BusinessWeek Online - Andrew Witty, the new chief executive of giant GlaxoSmithKline , surveys the wreckage of the global financial meltdown and sees an upside. With pharmaceutical stocks at record lows, it's a good time to acquire biotech companies and other assets that could drive Glaxo's growth for years. Its midsize rival Wyeth is also on the prowl -- but there's a difference. Faced with a shrinking market valuation, new CEO Bernard Poussot may have to bulk up to ward off larger predators.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Pligg is a Web 2.0 open source content management system
Comments